Call Karen if you are interested in the AE37/GP2 clinical trial!
 

Phase II Trial of the HER2/Neu Peptide GP2 + GM-CSF Vaccine vs GM-CSF Alone in HLA-A2+ OR the Modified HER2/Neu Peptide AE37 + GM-CSF Vaccine vs GM-CSF Alone in HLA-A2- Node-Positive and High-Risk Node-Negative Breast Cancer Patients





http://www.clinicaltrials.gov/ct2/show/NCT00524277?term=her2%2Fneu+vaccine&recr=Open&rank =5




Karen Escamilla, RN, BSN, CCRP
Regional Clinical Manager
Cancer Vaccine Development Program
San Antonio Military Medical Center
General Surgery Clinic
3551 Roger Brooke Drive
Ft. Sam Houston, TX 78234
210-916-4837
Email: karen.l.escamilla.ctr@us.army.mil